Ovarian cancer Trials in Vandœuvre-lès-Nancy, France
Conditions / Ovarian cancer / Vandœuvre-lès-Nancy, France
Clinical trials for Ovarian cancer investigate a range of treatment strategies and patient populations.
27 total trials for this combination
Showing top 10 of 27 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT02631876 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer | COMPLETED | PHASE3 |
| NCT02477644 | Platine, Avastin and OLAparib in 1st Line | COMPLETED | PHASE3 |
| NCT05059522 | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | ACTIVE_NOT_RECRUITING | — |
| NCT00976911 | AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | COMPLETED | PHASE3 |
| NCT02580058 | A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) | COMPLETED | PHASE3 |
| NCT03017573 | Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE) | RECRUITING | NA |
| NCT00483782 | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | COMPLETED | PHASE3 |
| NCT00866697 | Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | COMPLETED | PHASE3 |
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | RECRUITING | PHASE1/PHASE2 |